Audentes Therapeutics Garners $42,500,000 Series B Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ab240430-bac8-4099-b0d6-e4016c5cbf91 - Date
12/3/2014 - Company Name
Audentes Therapeutics - Mailing Address
101 Montgomery Street. San Francisco, CA 94104 USA - Company Description
Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology. - Website
http://www.audentestx.com - Transaction Type
Venture Equity - Transaction Amount
$42,500,000 - Transaction Round
Series B - Proceeds Purposes
The additional funding will allow Audentes to achieve key clinical development milestones for its two lead programs and to continue research and in-licensing efforts to become a worldwide leader in gene therapy. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
